Fremanezumab versus conventional preventive treatments as ≥2nd line prophylaxis of migraine – propensity score matched multiple cohort comparative retrospective longitudinal analyses of depersonalized 6-months real-world data of the German Pain e-Registry. (Freedom)

Study identification

• EU PAS number:
  EUPAS105823
• Study ID:
  105824
• Official title and acronym:
  Fremanezumab versus conventional preventive treatments as ≥2nd line prophylaxis of migraine – propensity score matched multiple cohort comparative retrospective longitudinal analyses of depersonalized 6-months real-world data of the German Pain e-Registry. (Freedom)
• DARWIN EU® study:
  No
• Study countries:
  Germany
• Study description:
  FREEDOM is an exploratory, non-interventional, post-marketing, open-label, retrospective parallel-group, flexible-dose, comparative longitudinal 24-week multiple-cohort-study using depersonalized data of the German Pain e-Registry (GPeR, until September 30, 2022) to assess the effectiveness of the calcitonin gene-related peptide antagonist fremanezumab compared to conventional medications used for the prophylactic treatment in adult patients with migraine who are deemed to be in need of an alternative preventive medication according to the mutual / shared decision of the responsible physician and affected patients.
• Study status:
  Finalised

Research institutions and networks

Institutions

Institute for Neurological Sciences (IFNAP)

Study timelines

Date when funding contract was signed

Planned: 03/10/2022

Actual: 03/10/2022

Study start date

Planned: 03/10/2022

Actual: 03/10/2022

Data analysis start date

Planned: 10/10/2022

Actual: 10/10/2022

Date of final study report

Planned: 31/03/2023

Actual: 31/03/2023

Sources of funding

Other

More details on funding

IFNAP - private institute of neurological sciences, O.Meany-MDPM GmbH

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable